Santaris Pharma’s HIF-1 Alpha Antagonist Begins Second Phase 1 Study against Solid Tumours and Lymphoma
News Nov 05, 2007
Santaris Pharma A/S announced the initiation of an open-label, non-randomized Phase 1 study with its HIF-1 alpha antagonist (EZN-2968) licensed outside Europe in 2006 to Enzon Pharmaceuticals, Inc. USA.
The study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 alpha anta¬gonist in a daily for 5 days schedule in approximately 30 patients with advanced solid tumors or lymphoma.
“We are very encouraged that Enzon Pharmaceuticals has initiated the second phase 1 study with EZN-2968, a novel RNA-targeted drug based on Santaris Pharmas Locked Nucleic Acid (LNA) technology,” said Keith McCullagh, CEO of Santaris Pharma A/S. “The early safety data on the ongoing cancer trial are encouraging and Enzon is now evaluating alternative dose schedules in this second human study in patients with advanced cancer.”
The investigational drug blocks the production of Hypoxia-inducible factor-1 alpha (HIF-1 alpha), a key regulator of a large number of genes important in cancer biology, including many involved in angio¬genesis, cell proliferation, apoptosis and cell invasion. HIF-1 alpha is low in normal cells, but ele¬vated in a variety of cancers. High expression of HIF-1 alpha is strongly correlated with poor prognosis and re¬sis¬tance to the¬rapy. Therefore, drugs that inhibit HIF-1 alpha are expected to block multiple mechanisms that control cancer progression.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Machine Learning: Helping Determine How a Drug Affects the BrainNews
Machine learning could improve our ability to determine whether a new drug works in the brain, potentially enabling researchers to detect drug effects that would be missed entirely by conventional statistical tests, finds a new UCL study published today in Brain.READ MORE